TrialNature medicine2026
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
Omar S Mabrouk et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this papercites it
TrialNature medicine2026
Omar S Mabrouk et al.PubMed ↗Publisher ↗
No numbers read from the abstract.